Effects of Simvastatin Alone or Combined With Ramipril on Nitric Oxide Bioactivity and Inflammation Markers in Hypercholesterolemic Patients.
10.4070/kcj.2003.33.11.1053
- Author:
Ji Won SON
1
;
Kwang Kon KOH
;
Seung Min YOU
;
Woun Seok RYU
;
Jeong Yeal AHN
;
Han Gyu KIM
;
Dae Sung KIM
;
Hyung Sik KIM
;
Kyu Jin OH
;
Eak Kyun SHIN
Author Information
1. Department of Cardiology, Gachon Medical School, Incheon, Korea.
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
HMG-CoA Reductase inhibitor;
Angiotensin converting enzyme inhibitor;
Endothelial function
- MeSH:
C-Reactive Protein;
Chemokine CCL2;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Hyperemia;
Inflammation*;
Lipoproteins;
Malondialdehyde;
Nitric Oxide*;
Plasma;
Ramipril*;
Simvastatin*
- From:Korean Circulation Journal
2003;33(11):1053-1059
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: Because the mechanisms of the biological effects of statin and antiotensin converting enzyme inhibitor therapies differ, the vascular responses to these therapies were studied in hypercholesterolemic patients. MATERIALS AND METHODS: Simvastatin, 20 mg, placebo or ramipril, 10 mg, were administered daily for 2 months, with a 2 month washout, to 32 hypercholesterolemic patients. This was a randomized, double-blind, placebo-controlled, crossover in design study. RESULTS: Simvastatin alone, or in combination with ramipril, significantly changed the lipoproteins, and improved the percentage of the flow-mediated dilator response to hyperemia by 46+/-48% and by 59+/-66%, respectively, relative to the baseline measurements (both p<0.001). The plasma malondialdehyde levels were reduced, relative to baseline measurements, by 6+/-57% (p=0.045) and 13+/-47% (p=0.045 and p<0.001, respectively) and plasma levels of monocyte chemoattractant protein-1 by 3+/-27% and by 9+/-16%, respectively (p=0.113 and p=0.001, respectively). The C-reactive protein were also reduced, relative to baseline measurements, by 17+/-75% and by 17+/-37%, respectively (p=0.003 and p=0.001, respectively). However, simvastatin combined with ramipril changed, to a greater extent, but was statistically insignificant, the percentage of the flow-mediated dilator response to hyperemia, and the plasma monocyte chemoattractant protein-1 levels, than simvastatin alone. CONCLUSION: Compared with simvastatin alone, the addition of ramipril improved the endothelial function to greater extent, but was statistically insignificant, in hypercholes-terolemic patients.
